PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood

NAActive, not recruitingINTERVENTIONAL
Enrollment

7,849

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2025

Conditions
Prenatal DisorderAneuploidy
Interventions
DIAGNOSTIC_TEST

Traditional integrated prenatal screening

biochemical prenatal screening with or without nuchal translucency by US

DIAGNOSTIC_TEST

Second-tier Non-invasive prenatal screening (NIPS)

genomics based NIPS after a positive traditional prenatal screen

DIAGNOSTIC_TEST

First-tier Non-invasive prenatal screening (NIPS)

genomics based NIPS at first trimester

DIAGNOSTIC_TEST

Invasive prenatal testing for fetal aneuploidy

amniocentesis or chorionic villi sampling (CVS)

Trial Locations (6)

V1Y 1P2

Kelowna Regional Fertility Center, Kelowna

V8J 2A6

Prince Rupert Regional Hospital, Prince Rupert

V6H 3N1

Children's & Women's Health Centre, Vancouver

H3T 1C5

CHU Ste-Justine, Montreal

G1L3L5

CHU de Québec - Université Laval, Québec

G4R 0N9

CIUSSS Côte-Nord, Sept-Îles

All Listed Sponsors
collaborator

Genome Quebec

OTHER

collaborator

Genome British Columbia

INDUSTRY

collaborator

Genome Alberta

OTHER

collaborator

Ontario Research Fund

OTHER

collaborator

Laval University

OTHER

collaborator

St. Justine's Hospital

OTHER

collaborator

Ottawa Hospital Research Institute

OTHER

collaborator

McGill University

OTHER

collaborator

University of British Columbia

OTHER

collaborator

University of Alberta

OTHER

collaborator

Genome Canada

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

CHU de Quebec-Universite Laval

OTHER